Mitomycin-C in the treatment of tracheal cicatrix after tracheal reconstruction.
OBJECTIVE
To demonstrate the potential use of Mitomycin-C (MMC) in the treatment of difficult and recurrent tracheal stenosis.


METHODS
Case series.


METHODS
Tertiary care setting.


METHODS
A retrospective chart review was performed on five pediatric patients with severe, recurrent tracheal granulation and cicatrix after tracheal reconstruction who were treated with topical MMC as an adjunct to bronchoscopy and laser treatment. MMC was applied intraoperatively on saturated pledgets at a dose of 0.1 mg/ml for 2 min to the area where the cicatrix had been lysed. The five patients were able to be decannulated.


CONCLUSIONS
Mitomycin-C is an anti metabolite known to inhibit fibroblast proliferation in vitro. This agent has been used with a high success rate in glaucoma filtration surgery to promote patency of the trabecula. The results of this preliminary application in the pediatric airway as well as the mechanism of action will be discussed.
Ward
R F
RF
Department of Otolaryngology, Cornell University Medical College, Manhattan Eye, Ear and Throat Hospital, New York, NY, USA. Ward10021@aol.com
April
M M
MM
D000287:Administration, Topical; D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D002921:Cicatrix / Q000188:drug therapy* / Q000628:therapy; D005260:Female; D006801:Humans; D008297:Male; D016685:Mitomycin / Q000008:administration & dosage* / Q000627:therapeutic use; D019384:Nucleic Acid Synthesis Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D012008:Recurrence; D014132:Trachea / Q000601:surgery; D014135:Tracheal Stenosis / Q000209:etiology / Q000517:prevention & control / Q000601:surgery*
D019384:Nucleic Acid Synthesis Inhibitors; D016685:Mitomycin